In the case of IL-2, it was approved for the treatment of advanced renal cell carcinoma and metastatic melanoma; regarding IFN-α, it was approved for the treatment of hairy cell leukemia, follicular non-Hodgkin’s lymphoma, melanoma, and AIDS-related Kaposi’s sarcoma [77]. Here, IL2 is linked to renal cell carcinoma.